Business Context and Reporting Period
Company: Prima BioMed Ltd (Note: The input text identifies the registrant as Prima BioMed Ltd, despite the request metadata mentioning IMMUTEP Ltd. Prima acquired Immutep SA in December 2014).
Reporting Period: Fiscal year ended June 30, 2016.
Business Overview: Prima BioMed is an Australian biotechnology company focused on developing immunotherapeutic products for cancer. Following the acquisition of Immutep SA, the company's portfolio centers on LAG-3 immune control mechanisms. Key product candidates include IMP321 (a recombinant protein in Phase IIb trials for metastatic breast cancer and Phase I for melanoma), IMP701 (licensed to Novartis), and IMP731 (licensed to GSK). The company suspended development of its former lead product, CVac, in February 2015 and subsequently licensed the assets to Sydys Corporation in May 2016.
Key Financial Metrics
| Metric (A$) | Fiscal 2016 | Fiscal 2015 |
|---|---|---|
| Revenue | 175,052 | 0 |
| Other Income | 1,853,869 | 2,092,867 |
| Total Revenue & Other Income | 2,028,921 | 2,092,867 |
| Net Loss | (62,015,184) | (32,151,696) |
| Loss Per Share (Basic/Diluted) | (2.77) cents | (2.02) cents |
| Cash and Cash Equivalents | 20,879,548 | 6,759,615 |
| Working Capital | 20,198,827 | 3,643,408 |
| Total Assets | 42,554,067 | 30,983,445 |
| Long-term Debt (Convertible Note) | 5,027,168 | 0 |
| Total Shareholders' Equity | 35,317,513 | 24,689,743 |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately A$30 million (93%) to A$62.0 million. This was primarily driven by a non-cash Share Based Payment expense of A$47.5 million related to a strategic investment from Ridgeback Capital Investments (convertible notes and warrants).
- Revenue Recognition: The company recorded A$175,052 in license revenue in 2016, compared to nil in 2015, stemming from an out-licensing deal of an intellectual property asset.
- Other Income Decline: Other income decreased by 11.4% to A$1.9 million, largely due to a reduction in grant income and the absence of foreign exchange gains recorded in the prior year.
- Expense Reductions: Research & Development expenses decreased by 21% to A$7.1 million due to the cessation of the costly CVac clinical trials, partially offset by the initiation of new IMP321 trials (AIPAC and TACTI-mel).
- Financing Costs: Finance costs dropped significantly from A$18.4 million in 2015 (related to the Bergen Global Opportunity Fund facility) to A$8,199 in 2016, as the Bergen facility was repaid/terminated.
- Liquidity Improvement: Cash and cash equivalents increased by A$14.5 million to A$20.9 million, driven by net cash provided by financing activities (A$25.7 million) from share issuances and convertible notes.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring substantial losses as it advances clinical trials for IMP321. The company anticipates requiring additional funding to achieve long-term commercialization goals.
- Capital Requirements: While current cash reserves (A$20.9 million) are deemed sufficient for operations for more than 12 months, the company plans to seek additional funding through public/private financings or licensing arrangements.
- NASDAQ Compliance: The company received a deficiency letter from NASDAQ in August 2016 regarding the Minimum Bid Price Rule (bid price below US$1.00). The company has 180 days to regain compliance; failure to do so could result in delisting.
- Key Risks:
- Development Risk: No products are currently approved for commercial sale; success depends on clinical trial outcomes and regulatory approvals.
- Financing Risk: Inability to raise sufficient capital could force the curtailment of operations.
- Market Risk: Exposure to foreign exchange fluctuations (USD and EUR) and volatility in share price.
- Intellectual Property: Reliance on patents and licenses (e.g., from Merck Serono) which may be challenged or expire.
Investor Verification Checklist
- Non-Cash Charges: Verify the impact of the A$47.5 million share-based payment expense on the reported net loss and its effect on diluted earnings per share.
- Cash Runway: Confirm the sufficiency of the A$20.9 million cash balance against the projected burn rate for the AIPAC and TACTI-mel clinical trials.
- NASDAQ Status: Monitor the company's progress in regaining compliance with the NASDAQ Minimum Bid Price Rule to avoid delisting.
- Convertible Note Terms: Review the terms of the Ridgeback Capital Investments convertible note (A$13.75 million face value) and associated warrants for potential future dilution.
- CVac Transaction: Assess the potential future milestone and royalty payments from the licensing of CVac assets to Sydys Corporation, noting the lack of upfront cash payment.